Maybe JNJ they dont have anything in Diabetes right? (insulin wise) Guessing.. I must say I can not find anything news wise today..and I can search like a hound dog..seems tighter then a steel drum..hmm
I have been chewing on this for some time...it is a marketing partner that Mannkind is seeking and JNJ does fit the bill as they do not have a current insulin line that Mannkinds Afrezza will canabalize out of existance... It does appear to me that BIOD is the cheaper deal as they have no more then 20k SQFT facility to produce and that imo is a poor negociation position to be partnering from...Sanofi may pick them up on the cheap..not sure that will be the best deal for stock holders...speculating..however..Mannkind seems to be positioned with financing..a double award winning production facility that can compartmentally expand as required..they have 10Billion of insulin..and can aquire an additional 10billion (sales worth) ..of course Mannkind imo will be a bigger deal in comparision to Biod...I also from recent news read that Mannkind is dealing with 6 bidders trying to widdle it down to the final 4 and that doesnt sound like Sanofi...dunno..well time will tell..